SALV Salvarx Group Plc

TIDMSALV

RNS Number : 5979O

SalvaRx Group plc

31 January 2019

SalvaRx Group plc

("SalvaRx" or the "Company")

Change of Nominated Adviser and Broker

SalvaRx (AIM: SALV), the drug discovery and development company focused on cancer immunotherapy, announces that pursuant to the proposed merger between SP Angel Corporate Finance LLP ("SP Angel") and Northland Capital Partners Ltd, it has appointed SP Angel as its Nominated Adviser and Joint Broker with immediate effect.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
  SalvaRx Group plc 
 Denham Eke, Chief Financial Officer           Tel: +44 (0) 01624 
                                                           639396 
 SP Angel Corporate Finance LLP              Tel: +44 (0) 20 3470 
  Nominated Adviser and Joint Broker                         0470 
 Matthew Johnson / Lindsay Mair (Corporate 
  Finance) 
 Peterhouse Capital Limited                  Tel: +44 (0) 20 7469 
  Joint Broker                                               0932 
  Lucy Williams / Duncan Vasey 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPFMGFMNGLGLZM

(END) Dow Jones Newswires

January 31, 2019 02:01 ET (07:01 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Nov 2024 to Dec 2024

Salvarx (LSE:SALV)
Historical Stock Chart
From Dec 2023 to Dec 2024